GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qurient Co Ltd (XKRX:115180) » Definitions » COGS-to-Revenue

Qurient Co (XKRX:115180) COGS-to-Revenue : 0.86 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Qurient Co COGS-to-Revenue?

Qurient Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ₩1,660 Mil. Its Revenue for the three months ended in Mar. 2025 was ₩1,920 Mil.

Qurient Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.86.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Qurient Co's Gross Margin % for the three months ended in Mar. 2025 was 13.58%.


Qurient Co COGS-to-Revenue Historical Data

The historical data trend for Qurient Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qurient Co COGS-to-Revenue Chart

Qurient Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.82 0.79 0.80 0.85

Qurient Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.82 0.86 0.89 0.86

Qurient Co COGS-to-Revenue Calculation

Qurient Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=7829.05 / 9179.834
=0.85

Qurient Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1659.615 / 1920.354
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qurient Co  (XKRX:115180) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Qurient Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 1659.615 / 1920.354
=13.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Qurient Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Qurient Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Qurient Co Business Description

Traded in Other Exchanges
N/A
Address
C-dong 8th Floor, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KOR, 13487
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.

Qurient Co Headlines

No Headlines